SHAPE-enabled fragment-based ligand discovery for RNA

被引:25
|
作者
Zeller, Meredith J. [1 ]
Favorov, Oleg [2 ]
Li, Kelin [3 ]
Nuthanakanti, Ashok [4 ]
Hussein, Dina [5 ]
Michaud, Aureliane [5 ]
Lafontaine, Daniel A. [5 ]
Busan, Steven [1 ]
Serganov, Alexander [4 ]
Aube, Jeffrey [1 ,3 ]
Weeks, Kevin M. [1 ]
机构
[1] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Chapel Hill, NC 27599 USA
[4] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA
[5] Univ Sherbrooke, Fac Sci, Dept Biol, RNA Grp, Sherbrooke, PQ J1K 2R1, Canada
基金
加拿大健康研究院;
关键词
RNA-targeted ligand discovery; SHAPE-MaP; cooperativity; fragment linking; SELECTIVE 2'-HYDROXYL ACYLATION; PRIMER EXTENSION; STRUCTURAL BASIS; DRUG DISCOVERY; NONCODING RNAS; BINDING; TRANSCRIPTION; RIBOSWITCHES; INHIBITORS; MAP;
D O I
10.1073/pnas.2122660119
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The transcriptome represents an attractive but underused set of targets for smallmolecule ligands. Here, we devise a technology that leverages fragment-based screening and SHAPE-MaP RNA structure probing to discover small-molecule fragments that bind an RNA structure of interest. We identified fragments and cooperatively binding fragment pairs that bind to the thiamine pyrophosphate (TPP) riboswitch with millimolar to micromolar affinities. We then used structure-activity relationship information to efficiently design a linked-fragment ligand, with no resemblance to the native ligand, with high ligand efficiency and druglikeness, that binds to the TPP thiM riboswitch with high nanomolar affinity and that modulates RNA conformation during cotranscriptional folding. Principles from this work are broadly applicable, leveraging cooperativity and multisite binding, for developing high-quality ligands for diverse RNA targets.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Innovations in targeting RNA by fragment-based ligand discovery
    Koehn, Jordan T.
    Felder, Simon
    Weeks, Kevin M.
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2023, 79
  • [2] fragment-based ligand discovery
    Fischer, Marcus
    Hubbard, Roderick E.
    MOLECULAR INTERVENTIONS, 2009, 9 (01) : 22 - 30
  • [3] Ligand efficiency and fragment-based drug discovery
    Bembenek, Scott D.
    Tounge, Brett A.
    Reynolds, Chades H.
    DRUG DISCOVERY TODAY, 2009, 14 (5-6) : 278 - 283
  • [4] Current perspectives in fragment-based ligand discovery
    Hubbard, Roderick
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2015, 71 : S37 - S37
  • [5] Fragment-Based Drug Discovery for RNA Targets
    Lundquist, Kasper P.
    Panchal, Vipul
    Gotfredsen, Charlotte H.
    Brenk, Ruth
    Clausen, Mads H.
    CHEMMEDCHEM, 2021, 16 (17) : 2588 - 2603
  • [6] Fragment-based ligand discovery meets phage display
    Erlanson, Daniel A.
    ACS CHEMICAL BIOLOGY, 2007, 2 (12) : 779 - 782
  • [7] Fragment-based Drug Discovery: the Shape of Things to Come
    Drysdale, Martin J.
    AUSTRALIAN JOURNAL OF CHEMISTRY, 2013, 66 (12) : 1544 - 1549
  • [8] Proteome-Wide Fragment-Based Ligand and Target Discovery
    Forrest, Ines
    Parker, Christopher G.
    ISRAEL JOURNAL OF CHEMISTRY, 2023, 63 (3-4)
  • [9] Molecular docking and ligand specificity in fragment-based inhibitor discovery
    Yu Chen
    Brian K Shoichet
    Nature Chemical Biology, 2009, 5 : 358 - 364
  • [10] Fragment-based screening: A new paradigm for ligand and target discovery
    Knight, Sinead
    Gianni, Davide
    Hendricks, Adam
    SLAS DISCOVERY, 2022, 27 (01) : 3 - 7